On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Advancing DehydraTECH Drug Delivery Platform, Innovative Products

Lexaria Bioscience is focusing on its pioneering DehydraTECH drug delivery technology The company boasts a portfolio of unique products Lexaria continues to conduct research regarding DehydraTECH technology for oral nicotine Based in Kelowna, British Columbia, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) focuses on technology for the improved delivery of bioactive compounds. Lexaria is the … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Advancing DehydraTECH Drug Delivery Platform, Innovative Products”

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Retains Oak Hill Financial Inc. for IR Services

Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) this morning announced that it has retained Oak Hill Financial Inc. to provide investor relations services to the company in compliance with regulatory guidelines. Per the update, Oak Hill is a Toronto-based firm that develops strategic platforms for its clients that … Continue reading “CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Retains Oak Hill Financial Inc. for IR Services”

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Renews Senior Management Contracts, Cancels Options

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced its successful negotiation of renewal management contracts with chief executive officer Chris Bunka and president John Docherty. According to the update, the new 3-year term contracts, for which specific details can be found within regulatory filings, provide management continuity … Continue reading “CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Renews Senior Management Contracts, Cancels Options”

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Technology Revolutionizes CBD Delivery

Biotechnology company Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) innovative drug-delivery platform DehydraTECH(TM) alters the way cannabinoids enter the bloodstream, which results in increased absorption. A recent article discussing LXRP reads, “Its proprietary technology promises multiple advantages in cannabinoid edibles. First, it masks the undesirable taste typically found in cannabinoid edibles, eliminating the need to add … Continue reading “CannabisNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Technology Revolutionizes CBD Delivery”

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Talks DehydraTECH’s Lifesaving Technology on CEO Clips

LXRP CEO Chris Bunka explained in the interview that proprietary technology can save 60,000 lives annually if consumption habits of even one percent of smokers worldwide change CEO Clips videos are featured on business sites including BNN Bloomberg, Thomson Reuters, Yahoo! Finance and Stockhouse.com Bunka went on to described LXRP’s growing patent portfolio and noted … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Talks DehydraTECH’s Lifesaving Technology on CEO Clips”

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Launches Its Largest Cannabinoid Research Program

The R&D program will focus on the proprietary Lexaria DehydraTECH delivery technology with the purpose of enhancing it further Results could contribute to new patent filings in the future; in addition, the program will examine more extensively the way DehydraTECH-enabled CBD outperforms generic CBD Lexaria-designed nanotech enhancements will also be included in the program Biotechnology … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Launches Its Largest Cannabinoid Research Program”

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) Utilizes Disruptive Technology for Improved Delivery of Bioactive Compounds

Biotechnology company and drug-delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTC: LXRP) utilizes disruptive technology for the improved delivery of bioactive compounds. A recent article discussing this reads, “Lexaria’s technology has been shown to be effective in numerous global studies, significantly assisting rapidity and quantity of absorption for a range of lipophilic (fat-soluble), bioactive molecules. … Continue reading “CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) Utilizes Disruptive Technology for Improved Delivery of Bioactive Compounds”

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Revolutionary Technology is Disrupting the Cannabis Edibles Industry

Lexaria Bioscience Corp. is the only company worldwide with patents issued for oral delivery of all cannabinoids Its proprietary technology bests traditional methods such as inhalation in several key ways The company continues to enhance its intellectual property portfolio as it pursues patents around the world Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a food … Continue reading “Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Revolutionary Technology is Disrupting the Cannabis Edibles Industry”

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) Launches its Largest Cannabinoid R&D Program

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTC: LXRP) on Wednesday announced that work has commenced on its largest-ever cannabinoid research program, which will also test Lexaria-designed nanotech enhancements. According to the update, the new program is comprised of 11 separate animal studies, each comparable in scope to individual animal studies … Continue reading “CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) Launches its Largest Cannabinoid R&D Program”

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Aims to Conduct Further Human Clinical Trials Following Positive TurboCBD Results

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) plans to conduct additional clinical trials using DehydraTECH(TM) in CBD after recently reporting noteworthy results of cardiovascular performance improvements with TurboCBD. A recent article discussing the company reads, “TurboCBD is Lexaria’s proprietary DehydraTECH-powered, CBD-fortified hemp-oil capsule. The capsules are formulated with full-spectrum hemp oil, ginseng and ginkgo for enhanced … Continue reading “CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Aims to Conduct Further Human Clinical Trials Following Positive TurboCBD Results”

Contact us: 303.498.7722